The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

After earlier talks failed to consummate a deal, U.S.-based drug maker Pfizer is now free to again pursue a bid for Britain’s AstraZeneca at the end of a mandatory three-month cooling-off period.
After earlier talks failed to consummate a deal, U.S.-based drug maker Pfizer is now free to again pursue a bid for Britain’s AstraZeneca at the end of a mandatory three-month cooling-off period.
(iStockPhoto/Getty)

Time pushes Pfizer and Astra further apart

A deal between Pfizer and AstraZeneca is looking a little harder following the three-month cooling-off period since takeover talks collapsed in May. Time has provided neither of the pharmaceutical groups with a decisive negotiating advantage if U.S.-based Pfizer takes the opportunity to renew friendly talks with its U.K. peer, as British M&A rules now permit.